Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01DK136762-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
The goal of this investigator-initiated, single-center, randomized controlled trial (RCT) is to compare the effects of four weeks of three therapies on clinical and mechanistic outcomes based on pH-Imp testing using a three-arm parallel design in NICU infants with objective GERD diagnosis. The three therapies being compared are natural maturation, proton pump inhibitor (PPI) use, and added rice (AR) formula use. The main goals are:
In consented subjects, eligibility is determined after initial diagnostic 24-hour pH Impedance test. These subjects will be randomized to one of the 3 arms of the study (natural maturation, PPI, AR formula) for 4 weeks of treatment. A second 24-hour pH Impedance test will be done on therapy at 4 weeks or before discharge, whichever occurs first. Primary outcome will also be measured at 4 weeks or at discharge, whichever comes first.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Natural maturation | No Intervention | Allows for time for infant maturation without treatment. | |
| Proton Pump Inhibitor (PPI) | Active Comparator | Omeprazole will be prescribed for 4 weeks using the dose of 1.5mg/kg/dose daily. |
|
| Added Rice (AR) Formula | Active Comparator | Added rice formula will be ordered as the infant diet for the 4-week treatment period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Omeprazole | Drug | Omeprazole will be the PPI prescribed for 4 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Achievement of primary outcome: Improvement or maintenance of oral feeding and/or absence of GERD symptoms (based on feeding method at inception) | Achievement of the primary outcome will be measured by treatment group to determine efficacy. For subjects on full oral feeds at inception, the primary outcome will be met if there is maintenance of oral feeds AND absence of associated GERD symptoms. For subjects receiving any tube feeding at inception, the primary outcome will be met if there is improvement in oral feeding (ratio of oral to tube feeds) OR absence of troublesome symptoms. The metric for measuring the absence of troublesome symptoms will be vomiting <2 times/day or coughing <18 times/day. | At 4 weeks of therapy or discharge, whichever occurs first |
| Decrease in ARI on treatment | Change in acid reflux index from time one pH impedance study (prior to treatment) to time 2 pH impedance study (during treatment) will be compared among treatment groups. | At time 2 study (4 weeks or prior to discharge, whichever is earliest) |
| Decreased frequency of GER events on treatment | Change in number of reflux events from time one pH impedance study (prior to treatment) to time 2 pH impedance study (during treatment) will be compared among treatment groups. | At time 2 study (4 weeks or prior to discharge, whichever is earliest) |
| Improvement (Increase) in distal baseline impedance on treatment | Change in distal baseline impedance from time one pH impedance study (prior to treatment) to time 2 pH impedance study (during treatment) will be compared among treatment groups. | At time 2 study (4 weeks or prior to discharge, whichever is earliest) |
| Decrease in symptom associated probability on treatment | Change in symptom associated probability from time one pH impedance study (prior to treatment) to time 2 pH impedance study (during treatment) will be compared among treatment groups. |
Not provided
Not provided
Inclusion Criteria:
NICU infants of any gestational age who are between 37 - 47 weeks postmenstrual age at inception of the study meeting the following requirements:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Erika K Osborn | Contact | 6143556667 | erika.osborn@nationwidechildrens.org | |
| Patty Luzader | Contact | 6143556627 | patty.luzader@nationwidechildrens.org |
| Name | Affiliation | Role |
|---|---|---|
| Sudarshan R sudarshan.jadcherla@nationwidechildrens.org | Nationwide Children's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nationwide Children's Hospita | Recruiting | Columbus | Ohio | 43215 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42277732 | Derived | Jadcherla SR, Osborn EK, Sultana Z, Helmick R, Sanchez JB, Slaughter JL, Wei L, Di Lorenzo C. GERD management in neonatal ICU infants: study protocol for a randomized controlled trial comparing maturation, added rice starch formula and proton pump inhibitors. BMC Pediatr. 2026 Jun 11. doi: 10.1186/s12887-026-07120-x. Online ahead of print. |
Not provided
Not provided
Will revisit at a later date
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009853 | Omeprazole |
| ID | Term |
|---|---|
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Infants will be randomized to one of three arms: Natural maturation, Proton Pump Inhibitor (PPI) treatment, or Added rice (AR) formula. Subjects will be stratified and allocated 1:1:1 based on tube feeds (yes or no) and ARI (3-7% or >7%).
Not provided
Not provided
Not provided
Not provided
| AR formula | Other | Added rice formula will be ordered for 4 weeks. |
|
| At time 2 study (4 weeks or prior to discharge, whichever is earliest) |
| D011725 |
| Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |